Date: 2018-01-22
Type of information: Collaboration agreement
Compound: antibodies using Iontas’ proprietary Mammalian Display Technology
Company: Iontas (UK) Sanofi (France)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism: monoclonal antibody
Disease:
Details:
- • On January 22, 2018, Iontas, a leader in the discovery and optimisation of fully human antibodies, announced that it has signed an agreement with Sanofi to discover antibodies using Iontas’ proprietary Mammalian Display Technology.
- Iontas’ platform allows for the construction of large libraries of monoclonal cell lines each displaying a different IgG-formatted antibody on the cell surface. Novel binders can be isolated from the libraries by using fluorescence-activated cell sorting on the basis of antigen binding. Importantly, the system also has the potential to identify clones with development liabilities, such as self-aggregation, during the initial discovery phase.
Financial terms:
Latest news:
Is general: Yes
